Weight Loss Surgery Expert Dr. Stephen J. McColgan Joins DAL International's Medical Advisory Board
Posted on: Tuesday, 14 August 2007, 09:20 CDT
DAL International Ltd. (PINKSHEETS: DALN) announces the appointment of Dr. Stephen J. McColgan as Director of its Medical Advisory Board on Weight Loss.
Dr. McColgan sports an impressive resume and is considered an expert in various weight loss surgeries. He has practiced medicine for 20 years and has held the position of Chairman of the Department of Surgery for Bellflower Medical Center for the past 10 years. He received his medical degree from the Boston University School of Medicine and an MBA from the University of California, Irvine.
CEO, Dr. Leatherman said, "We are excited and honored to have Dr. McColgan as part of our medical advisory board. His 20 years of medical practice experience and expertise on various weight loss surgeries will be invaluable as he advises the Company and its Medical Travel International division on state-of-the-art and cutting edge technologies for effective and successful weight loss."
About DAL International
DAL International Ltd., is traded under the ticker symbol (PINKSHEETS: DALN) and is headquarted in Las Vegas, Nevada. DAL's mission is to become a leader within the medical travel and weight loss industry. This will be done by enhancing each client's quality of life through the combined use of medical expertise that delivers specialized, state-of-the-art, world class and affordable medical care and expanded treatment options through a Premier International network of physicians and hospitals that unite across national borders.
This press release contains forward-looking statements, which are made pursuant to the Safe Harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different. Factors include, but are not limited to, available funding, market acceptance, competition, recruitment and retention of personnel, dependence on key personnel and certain risks associated with the projects in which the Company is engaged to complete and others. The forward-looking statements should be considered in light of these risks and uncertainties. The Company disavows any obligation to update or correct any of its forward-looking statements.
For more information visit us online at www.DALLTD.com.
D. A. Leatherman, D.C. Phone: 1-800-501-0024 Fax: 1-760-328-5340 eMail: Email Contact
SOURCE: DAL International Ltd.
Source: MARKET WIRE
Related Articles
- DOBI Medical International Reports 2005 Year-End Results
- DOBI Medical International to Present at the C.E. Unterberg, Towbin Life Sciences Conference
- DOBI Medical International to Present at Leading Angiogenesis Conference
- DOBI Medical International to Present at the Arch Investment Conference
- DOBI Medical International Progresses With ComfortScan(R) PMA Clinical Trial
- DOBI Medical International to Present at the NYSSA Medical Services Conference
- DOBI Medical International Announces Fall 2005 Scientific and Investment Conference Participation Schedule
- DOBI Medical International Receives ISO 13485:2003 Certification and Renews Canadian Quality System Certifications
- DOBI Medical International Progresses With ComfortScan(TM) Clinical Trial
- DOBI Medical International to Present at CEUT Emerging Growth Opportunities Conference
User Comments (0)

RSS Feeds